Doctolib’s Story: From Revolutionary Idea to French Unicorn (2013-2025)

Doctolib has become in barely twelve years one of French Tech’s most remarkable success stories, radically transforming how French people make their medical appointments. Look back at the epic of a startup that revolutionized the digital health sector.

Origins: A Vision Born from Experience

Doctolib’s story begins in August 2013 with the meeting of four entrepreneurs with complementary profiles. Stanislas Niox-Chateau, former tennis champion turned financial analyst at Otium Capital after his HEC studies, carries the initial idea. Strong from his successful experience with La Fourchette, he identifies a major problem in the French healthcare system: the complexity of medical appointment booking.

Stanislas partners with Jessy Bernal, Ivan Schneider and Steve Abou-Rjeily to create Doctolib in December 2013. From the start, the approach is pragmatic: they surround themselves with 50 partner practitioners (doctors and dentists) who become their first users and provide valuable feedback to refine the product.

2014-2016: Solid Foundations

The first year marks a decisive turning point. In February 2014, Doctolib raises €1 million from historic investors, notably Antoine Freysz and Bertrand Jelensperger. In June, the service is deployed in its first clinic, thus validating the concept.

2015 confirms the potential with a new fundraising of €4 million bringing the total to €5 million raised in one year. This growth allows the company to open offices in 10 French cities and double its workforce, going from 50 to 100 employees.

In 2016, Doctolib crosses a major step with its establishment in Germany and a fundraising of €26 million from Accel Partners and Bpifrance. This international expansion testifies to the company’s European ambition.

2017-2018: Acceleration and Consolidation

2017 is marked by sustained growth with a new fundraising of €26 million more. But it’s in July 2018 that Doctolib strikes a big blow by acquiring its main French competitor, MonDocteur, for approximately €45 million.

This strategic acquisition is crucial: it allows Doctolib to consolidate its leadership position with 55,000 practitioner users and 20 million patient visits per month. The new ensemble employs 600 employees and positions itself as “the most used online medical appointment booking service in the world”.

2019-2020: Consecration and COVID Trial

In March 2019, Doctolib reaches the highly coveted status of French unicorn with a €150 million fundraising that values the company at over one billion euros. This milestone coincides with the launch of teleconsultation services, developed with 500 partner doctors.

But it’s the COVID-19 pandemic in 2020 that definitively propels Doctolib to the forefront. The platform plays a crucial role in managing the health crisis, notably for organizing vaccination campaigns. The explosion of teleconsultation (4.5 million acts between March and September 2020, 45 times more than in 2019) consolidates its position.

2021-2022: European Expansion and French Record

In October 2021, Doctolib concretizes its European expansion by acquiring Dottori.it, one of Italy’s main medical appointment booking actors. This acquisition is accompanied by an investment plan of €250 million and hiring 500 people in Italy.

March 15, 2022 marks financial peak with a mega-fundraising of €500 million that propels valuation to €5.8 billion. Doctolib thus becomes the best-valued French startup, surpassing Back Market. This fundraising aims to create 3,500 jobs in France, Germany and Italy over five years.

2023: The Trial of Controversies

2023 is marked by a major controversy around the presence of naturopaths and alternative medicine practitioners on the platform. Facing medical community criticism denouncing dangerous practices, Doctolib makes a radical decision in October 2022: exclude 5,700 practitioners without ADELI or RPPS number.

This decision, hailed by the medical body, results in a 32% revenue drop for some excluded naturopaths. But it allows Doctolib to consolidate its medical credibility and refocus on regulated healthcare professionals.

2024-2025: The AI Era and March Toward Profitability

In October 2024, Doctolib launches a major innovation: the AI-based Consultation Assistant. This revolutionary tool automates note-taking during consultations, allowing doctors to focus more on their patients.

2024 figures reveal a company in full maturity: €348 million annual recurring revenue (+22.5% compared to 2023), but still €53.8 million EBITDA losses, although reducing compared to 2023’s €87.1 million.

2025 announces itself as the pivotal year: Doctolib finally targets profitability after twelve years of massive investments. A stock market introduction is mentioned for 2025 or 2026, which could be one of French Tech’s most anticipated IPOs.

Economic Model Centered on Professionals

Contrary to popular belief, 99% of Doctolib’s revenue comes from healthcare professional subscriptions, not from patients who use the platform for free. With a subscription at €129 including tax per month for medical practices, Doctolib now equips 300,000 healthcare professionals and 1,700 establishments in Europe.

Challenges and Future Perspectives

Despite its success, Doctolib faces several challenges. Competition intensifies with actors like DocPlanner in Europe or French alternatives like GPS Santé offering more attractive rates. The risk of medicine uberization and data protection questions remain major concerns.

The company bets on artificial intelligence to maintain its lead, with projects like the intelligent answering machine planned for 2025. European expansion continues, with 45 million users in France, 10 million in Germany and 5 million in Italy.

Conclusion: An Exemplary French Success Story

From Parisian startup to European unicorn, Doctolib embodies French entrepreneurship success in digital health. In twelve years, the company raised nearly €900 million, revolutionized medical appointment booking for millions of Europeans and created thousands of jobs.

Today valued at €5.8 billion, Doctolib prepares to cross a new step with the profitability objective in 2025 and a possible stock market introduction. A trajectory confirming French Tech’s potential to create European champions in strategic sectors like health.